Takeda's Orzeyful is the first-in-class orexin agonist cleared to treat narcolepsy type 1 at its root cause — and Jefferies pegs peak sales near $2 billion.
The FDA approved GENGLYCOS, Ultragenyx's first gene therapy and the first treatment for the root cause of glycogen storage disease type Ia. The headline result: 31% less daily cornstarch.
Bristol Myers Squibb's Zenbexus is the first CELMoD approved for multiple myeloma — cleared on a doubled deep-remission rate (41% vs 21%) and priced at $29,500 a cycle.
Jazz Pharmaceuticals is paying $820M upfront — up to $1.32B — for Actio Biosciences and its Phase 1 KCNT1 epilepsy drug, aimed at just ~2,500 U.S. patients.
After two rejections, Replimune's tumor-injected virus Tudriqev won accelerated FDA approval on August 6 — a 24.2% response rate in melanoma that had beaten standard immunotherapy.
The FDA just approved mFlusiva, the first mRNA flu vaccine ever — 26.6% more effective than the standard shot in adults 50+, six months after the agency refused to review it.
Pathos AI committed up to $2.2 billion to license cancer drugs from Alphamab and AstraZeneca without inventing a single molecule. Inside the bet that AI's real job is picking patients, not chemistry.
Lilly and its manufacturing partner Resilience are putting $750 million into an Ohio campus to make more of the injector pens behind the diabetes and obesity boom -- 400 new jobs, full operations by early 2027.
Celcuity's first FDA drug, REVTORPYK, cut breast-cancer progression risk 76% and stretched median control from 2.0 to 9.3 months — yet the stock slid on a delayed launch and rough side effects.
Lilly's triple-G shot retatrutide hit 30.3% weight loss in Phase 3 — surgery territory. Then the FDA filing slipped to Q1 2027 over manufacturing.
Eli Lilly's triple-agonist shot retatrutide hit 22.6% weight loss in two more Phase 3 trials — its fifth straight win, with an FDA filing due Q1 2027.
Merck's Lipfendra (enlicitide) is the first oral PCSK9 inhibitor — a once-daily pill that cuts LDL up to 59%, matching the injectables at $315 a month.
